FMP
Millendo Therapeutics, Inc.
MLND
NASDAQ
Inactive Equity
Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.
1.06 USD
-0.06000006 (-5.66%)
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-1.35M
-2.8M
-1.99M
-3.7M
-4.22M
-
-
-
-
-
100
100
100
100
100
100
100
100
100
-
-
-1.8k
-149.78k
-
-
-
-
-
-
100
100
100
100
100
-
-
-
-
-1.35M
-2.8M
-2M
-3.85M
-4.22M
-
-
-
-
-
0.3
4.9M
4.15
4.15
0
1.47M
1.47M
0
100
5.8
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
-
-
-
-
-
-
-
-
-
-
-1.35M
-2.8M
-1.99M
-3.7M
-4.22M
-
-
-
-
-
-
-
-1.8k
-149.78k
-
-
-
-
-
-
-1.35M
-2.8M
-2M
-3.85M
-4.22M
-
-
-
-
-
5.8
5.8
5.8
5.8
5.8
-
-
-
-
-
-
5.8
0
0
0
0
-1.84M
1.84M
4.9M
0.38
0.3752 0.2%